126 related articles for article (PubMed ID: 26776834)
1. Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.
Sestito R; Cianfrocca R; Rosanò L; Tocci P; Di Castro V; Caprara V; Bagnato A
Life Sci; 2016 Aug; 159():43-48. PubMed ID: 26776834
[TBL] [Abstract][Full Text] [Related]
2. Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy.
Rosanò L; Cianfrocca R; Tocci P; Spinella F; Di Castro V; Caprara V; Semprucci E; Ferrandina G; Natali PG; Bagnato A
Cancer Res; 2014 Dec; 74(24):7453-64. PubMed ID: 25377471
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
4. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.
Sestito R; Cianfrocca R; Rosanò L; Tocci P; Semprucci E; Di Castro V; Caprara V; Ferrandina G; Sacconi A; Blandino G; Bagnato A
Oncotarget; 2016 Jan; 7(4):4009-23. PubMed ID: 26675258
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer.
Tocci P; Caprara V; Cianfrocca R; Sestito R; Di Castro V; Bagnato A; Rosanò L
Life Sci; 2016 Aug; 159():49-54. PubMed ID: 26776837
[TBL] [Abstract][Full Text] [Related]
6. Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.
Lee HJ; Hanibuchi M; Kim SJ; Yu H; Kim MS; He J; Langley RR; Lehembre F; Regenass U; Fidler IJ
Neuro Oncol; 2016 Apr; 18(4):486-96. PubMed ID: 26995790
[TBL] [Abstract][Full Text] [Related]
7. β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells.
Cianfrocca R; Tocci P; Semprucci E; Spinella F; Di Castro V; Bagnato A; Rosanò L
Life Sci; 2014 Nov; 118(2):179-84. PubMed ID: 24530737
[TBL] [Abstract][Full Text] [Related]
8. Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer.
Sestito R; Cianfrocca R; Tocci P; Rosanò L; Sacconi A; Blandino G; Bagnato A
Commun Biol; 2020 Nov; 3(1):677. PubMed ID: 33188287
[TBL] [Abstract][Full Text] [Related]
9. The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
Cianfrocca R; Tocci P; Spinella F; Di Castro V; Bagnato A; Rosanò L
Life Sci; 2012 Oct; 91(13-14):550-6. PubMed ID: 22480520
[TBL] [Abstract][Full Text] [Related]
10. Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma.
Semprucci E; Tocci P; Cianfrocca R; Sestito R; Caprara V; Veglione M; Castro VD; Spadaro F; Ferrandina G; Bagnato A; Rosanò L
Oncogene; 2016 Jun; 35(26):3432-42. PubMed ID: 26522724
[TBL] [Abstract][Full Text] [Related]
11. Targeting the endothelin axis as a therapeutic strategy for oral cancer metastasis and pain.
Dang D; Ye Y; Aouizerat BE; Patel YK; Viet DT; Chan KC; Ono K; Doan C; Figueroa JD; Yu G; Viet CT
Sci Rep; 2020 Nov; 10(1):20832. PubMed ID: 33257729
[TBL] [Abstract][Full Text] [Related]
12. IGF1R-α6 integrin-S100A4 network governs the organ-specific metastasis of chemoresistant epithelial ovarian cancer cells.
Deo AN; Thorat R; Dhadve AC; De A; Rekhi B; Ray P
Biochim Biophys Acta Mol Basis Dis; 2022 Jan; 1868(1):166282. PubMed ID: 34600083
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
14. Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer.
Cianfrocca R; Rosanò L; Tocci P; Sestito R; Caprara V; Di Castro V; De Maria R; Bagnato A
Cell Death Differ; 2017 Oct; 24(10):1811-1820. PubMed ID: 28708138
[TBL] [Abstract][Full Text] [Related]
15. Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer.
Sestito R; Tocci P; Roman C; Di Castro V; Bagnato A
J Exp Clin Cancer Res; 2022 Apr; 41(1):157. PubMed ID: 35477522
[TBL] [Abstract][Full Text] [Related]
16. Transfer and Vascular Effect of Endothelin Receptor Antagonists in the Human Placenta.
Hitzerd E; Neuman RI; Broekhuizen M; Simons SHP; Schoenmakers S; Reiss IKM; Koch BCP; van den Meiracker AH; Versmissen J; Visser W; Danser AHJ
Hypertension; 2020 Mar; 75(3):877-884. PubMed ID: 31884859
[TBL] [Abstract][Full Text] [Related]
17. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.
Cipriani P; Di Benedetto P; Ruscitti P; Verzella D; Fischietti M; Zazzeroni F; Liakouli V; Carubbi F; Berardicurti O; Alesse E; Giacomelli R
Arthritis Res Ther; 2015 Sep; 17(1):247. PubMed ID: 26357964
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
[TBL] [Abstract][Full Text] [Related]
19. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
[TBL] [Abstract][Full Text] [Related]
20. Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Kim SJ; Lee HJ; Kim MS; Choi HJ; He J; Wu Q; Aldape K; Weinberg JS; Yung WK; Conrad CA; Langley RR; Lehembre F; Regenass U; Fidler IJ
Clin Cancer Res; 2015 Oct; 21(20):4630-41. PubMed ID: 26106074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
